Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PEAK family member 3 (PEAK3) is a pseudokinase and molecular scaffold protein, part of the PEAK family (NKF3) along with PEAK1 and PEAK2/Pragmin[1][4][5]. PEAK3 is structurally similar to other family members but is unique in its domain features and binding interfaces, including a fully resolved activation loop and αC helix. It acts as a signaling hub downstream of growth factor stimulation and is dynamically regulated by phosphorylation, especially through interactions with 14-3-3 proteins, CrkII, and other scaffold/adaptor proteins. PEAK3 dimerizes through a conserved SHED domain, forming homo- and heterodimers. Functionally, PEAK3 controls cell motility, migration, and morphology, and its overexpression has been shown to promote invasive, oncogenic behaviors in several cancer cell models. Recent cryo-EM studies highlight its complex with regulatory proteins such as 14-3-3, impacting localization and interactome diversity. PEAK3 is increasingly viewed as an important disease target, particularly in oncology, though no therapeutic interventions have yet been reported[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PEAK family member 3 (PEAK3).